 | |
| Clinical data | |
|---|---|
| Other names | PF-2545920 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C25H20N4O |
| Molar mass | 392.462 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Mardepodect (developmental code namePF-2545920) is a drug which was developed byPfizer for the treatment ofschizophrenia. It acts as aphosphodiesterase inhibitor selective for thePDE10A subtype.[1]
The PDE10A enzyme is expressed primarily in the brain, mostly in thestriatum,nucleus accumbens andolfactory tubercle, and is thought to be particularly important in regulating the activity ofdopamine-sensitive medium spiny neurons in the striatum which are known to be targets of conventionalantipsychotic drugs.[2] Older PDE10A inhibitors such aspapaverine have been shown to produce antipsychotic effects in animal models,[3] and more potent and selective PDE10A inhibitors are a current area of research for novel antipsychotic drugs which act through a different pathway to conventional dopamine or5-HT2A antagonist drugs and may have a more favourable side effects profile.[4]
Mardepodect is currently one of the furthest advanced PDE10A inhibitors in development and has progressed through to Phase IIclinical trials in humans.[5] In 2017, development of mardepodect for the treatment of schizophrenia andHuntington's disease was discontinued.[6]
